Department of Medicine, University of Illinois at Chicago, Chicago, IL, United States of America.
Department of Medicine, University of Illinois at Chicago, Chicago, IL, United States of America.
Biochem Pharmacol. 2013 Mar 1;85(5):644-652. doi: 10.1016/j.bcp.2012.10.013. Epub 2012 Oct 24.
Oncogenic transcription factor FOXM1 is overexpressed in the majority of human cancers. In addition, FOXM1 has been implicated in cell migration, invasion, angiogenesis and metastasis. The important role of FOXM1 in cancer affirms its significance for therapeutic intervention. Current data suggest that targeting FOXM1 in mono- or combination therapy may have promising therapeutic benefits for the treatment of cancer. However, challenges with the delivery of anti-FOXM1 siRNA to tumors and the absence of small molecules, which specifically inhibit FOXM1, are delaying the development of FOXM1 inhibitors as feasible anticancer drugs. In this review, we describe and summarize the efforts that have been made to target FOXM1 in cancer and the consequences of FOXM1 suppression in human cancer cells.
致癌转录因子 FOXM1 在大多数人类癌症中过度表达。此外，FOXM1 已被牵连到细胞迁移、侵袭、血管生成和转移中。FOXM1 在癌症中的重要作用证实了其在治疗干预中的重要性。目前的数据表明，在单一或联合治疗中靶向 FOXM1 可能对癌症的治疗具有有前景的治疗益处。然而，将抗 FOXM1 siRNA 递送到肿瘤中的挑战以及缺乏专门抑制 FOXM1 的小分子，都延缓了 FOXM1 抑制剂作为可行抗癌药物的发展。在这篇综述中，我们描述并总结了针对癌症中的 FOXM1 所做的努力，以及抑制人癌细胞中的 FOXM1 的后果。
